Clinical trials: Bipolar Disorder With Psychotic Features
Bipolar I Disorder, Mania
An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania
The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving manic symptoms in adults with bipolar I disorder who are currently experiencing an episode of mania with or…
- Trial name
- NCT07288320
- Testing
- NBI-1117568
- Where
- 11 sites in United States
- Volunteers
- 150 people
- Sponsor
- Neurocrine Biosciences
Prodromal Schizophrenia, Psychotic Disorders
Psychosis: Early Detection, Intervention and Prevention
The primary aim of this application is to conduct a randomized, controlled clinical trial of a specialized mental health service delivery system specifically developed for prodromal psychotic disorders.
- Conditions
- Prodromal Schizophrenia, Psychotic Disorders, Severe Bipolar Disorder With Psychotic Features, Severe Major Depression With Psychotic Features
- Trial name
- EDIP (NCT01597141)
- Testing
- Family-aided Assertive Community Treatment, Enhanced standard treatment
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- MaineHealth
Schizophrenia, Schizoaffective Disorder
Academic-Community EPINET (AC-EPINET)
The investigators propose to examine the effects of CSC services delivered via TH (CSC-TH) versus the standard clinic-based CSC model (CSC-SD) on engagement and outcomes in a 12-month, randomized trial.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Major Depression With Psychotic Features
- Trial name
- AC-EPINET (NCT04497857)
- Testing
- Coordinated Specialty Care (CSC)
- Where
- 6 sites in United States
- Volunteers
- 74 people
- Sponsor
- Indiana University
Bipolar Disorder, Schizoaffective Disorder
Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features
Aim: In a population of first episode manic patients with psychotic features, we want to compare the side effect profile, the degree of adherence and the subjective well being, as well as the efficacy of two treatments: The…
- Trial name
- NCT00202293
- Testing
- Olanzapine, Lithium, Chlorpromazine
- Where
- Australia
- Volunteers
- 83 people
- Sponsor
- Melbourne Health
Schizophrenia, Bipolar Disorder
Aripiprazole Open-Label, Safety and Tolerability Study
The purpose of this study is to test the long-term safety and tolerability of aripiprazole in adolescent patients with schizophrenia, and child and adolescent patients with bipolar I disorder, manic or mixed episode.
- Trial name
- APEX 241 (NCT00102518)
- Testing
- Aripiprazole
- Where
- 50 sites in United States
- Volunteers
- 325 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar Disorder
Aripiprazole in Children and Adolescents With Bipolar I Disorder
The purpose of this trial is to test the safety and efficacy of two doses of aripiprazole in child and adolescent patients with bipolar I disorder, manic or mixed episode with or without psychotic features.
- Trial name
- NCT00110461
- Testing
- Aripiprazole
- Where
- 53 sites in United States
- Volunteers
- 296 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Psychosis
Minnesota Community-Based Cognitive Training in Early Psychosis
The purpose of this study is to determine whether cognitive training exercises can improve cognitive functioning in young patients with recent-onset psychosis who are being treated in community mental health settings using the…
- Conditions
- Schizophrenia, Psychosis, Schizoaffective Disorder, Schizophreniform Disorders
- Trial name
- Mini-COTES (NCT03079024)
- Testing
- Targeted Cognitive Training, General Cognitive Exercises, Coordinated Specialty Care for First Episode Psychosis
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Minnesota
Schizophrenia, Bipolar Disorder
Early Detection and Intervention for the Prevention of Psychosis
EDIPP is a multisite trial of early identification and intervention to prevent the onset of psychosis in adolescents and young adults, carried out at six sites across the United States.
- Conditions
- Schizophrenia, Bipolar Disorder, Depression, Psychotic Disorders
- Trial name
- EDIPP (NCT00531518)
- Testing
- aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine, Psychoeducational multifamily group treatment, Supported employment and education
- Where
- 6 sites in United States
- Volunteers
- 292 people
- Sponsor
- MaineHealth
Schizophrenia, Schizophreniform Disorder
Integrated Care in Psychotic Disorders With Severe Mental Illness
The study examine the effectiveness of an integrated care program including therapeutic assertive community treatment (ACT) for people with psychotic disorders fulfilling severe and persistent mental illness (SPMI, ACCESS-II…
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder
- Trial name
- ACCESS-II (NCT01888627)
- Testing
- Integrated care
- Where
- Germany
- Volunteers
- 400 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Schizophreniform Disorder, Schizoaffective Disorder
Open-label Ziprasidone Study for Psychosis Treatment in Adolescents
This open-label study will assess the medication Geodon® (Ziprasidone) in pediatric patients, aged 13-17, diagnosed with psychotic disorder.
- Conditions
- Schizophreniform Disorder, Schizoaffective Disorder, Psychosis, Depressive Disorder, Major
- Trial name
- NCT00421954
- Testing
- Ziprasidone
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- New York State Psychiatric Institute
Schizophreniform Disorder, Bipolar I Disorder
Prevention of Weight Gain in Early Psychoses
The purpose of this study is to determine whether individuals with psychotic spectrum disorders ( Schizophrenia, Schizoaffective disorder,Schizophreniform Disorder, Bipolar Disorder (Type I),Bipolar Disorder (Type II),Major…
- Conditions
- Schizophreniform Disorder, Bipolar I Disorder, Bipolar II Disorder, Major Depressive Disorder
- Trial name
- NCT01075295
- Testing
- Behavioural Intervention for the Prevention of Weight Gain, TAU
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- Centre for Addiction and Mental Health
Recent-Onset Psychosis, Schizophrenia
Multifamily Psychoeducation and Cognitive Remediation for Recent-Onset Psychosis
The goal of this study is to determine whether pairing multifamily group psychoeducation with cognitive remediation may facilitate improved outcomes among individuals with recent-onset psychosis.
- Conditions
- Recent-Onset Psychosis, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder With Psychotic Features
- Trial name
- NCT01196286
- Testing
- Multifamily Group Psychoeducation (MFG), Cognitive Remediation (CR)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Arizona
Schizophrenia, Schizoaffective Disorder
Effects of Risperidone and Olanzapine on Patients With Schizophrenia, Schizoaffective Disorder, Major Depression or Bipolar Disorder
This twelve month, open-label study considers the effect of Risperdal (risperidone) versus Zyprexa (olanzapine) on weight gain, physical health, and outcome in a population of those diagnosed with schizophrenia, schizoaffective…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Depressive Disorder, Major, Bipolar Disorder
- Trial name
- NCT00179062
- Testing
- olanzapine versus risperidone
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Vanderbilt University
Schizophrenia, Schizoaffective Disorder
Impact of Medication Education on Adherence and Side Effects
Severe mental disorders such as schizophrenia, bipolar disorder, and psychotic depression often require long-term or lifelong medication treatment.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder With Psychotic Features, Major Depressive Disorder With Psychotic Features
- Trial name
- MED-ADHERE (NCT07374588)
- Testing
- Medication Education Program, Routine Psychiatric Inpatient Care
- Where
- Turkey (Türkiye)
- Volunteers
- 64 people
- Sponsor
- Cumhuriyet University
Adolescent Schizophrenia, Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features
Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.
This is an open-label study consisting of a screening period, a conversion/titration phase (Phase 1), an open-label treatment phase (Phase 2), and a follow-up period.
- Trial name
- ATTAIN 267 (NCT01122927)
- Testing
- Aripiprazole
- Where
- 101 sites in United States, Bulgaria and 11 more
- Volunteers
- 524 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
Reducing Internalized Stigma in People With Serious Mental Illness
The purpose of this study is to determine if Ending Self-Stigma (ESS), a 9-session group intervention designed to assist veterans with serious mental illness to develop skills (SMI) to effectively cope with stigma and minimize…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression With Psychotic Features
- Trial name
- ESS (NCT01259427)
- Testing
- Ending Self Stigma (ESS), Health and Wellness Group
- Where
- 3 sites in United States
- Volunteers
- 252 people
- Sponsor
- VA Office of Research and Development
Psychosis, Schizophrenia Disorder
Cognitive Strategies in Early Psychosis 2
The goal of this clinical trial is to learn more about decision making in psychosis spectrum disorders, like schizophrenia. Participants will be people who have had symptoms of a psychosis spectrum disorder start within the last…
- Conditions
- Psychosis, Schizophrenia Disorder, Schizoaffective Disorder, Major Depressive Disorder With Psychotic Features
- Trial name
- COSTEP 2 (NCT07263022)
- Testing
- Modafinil, D-serine solution
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Minnesota
Psychosis, Psychosis Nos/Other
EPI-MINN: Targeting Cognition and Motivation - National
The purpose of this study is to perform a practice-based research project designed to assess whether cognition and motivated behavior in early psychosis can be addressed as key treatment goals within real-world settings by using…
- Conditions
- Psychosis, Psychosis Nos/Other, Schizophrenia, Schizo Affective Disorder
- Trial name
- NCT05877716
- Testing
- Cognitive and Social Cognitive Training, Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App, Early Psychosis Coordinated Specialty Care
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- University of Minnesota
Schizophrenia and Disorders With Psychotic Features, Affective Psychosis, Bipolar
Duration of Untreated Psychosis (DUP) and Pathways to Care in Nordland
During the 1990s, evidence began to emerge of the long duration of untreated illness prior to receiving treatment for patients with psychotic disorders.
- Conditions
- Schizophrenia and Disorders With Psychotic Features, Affective Psychosis, Bipolar, Psychoses
- Trial name
- NCT01196858
- Where
- Norway
- Volunteers
- 62 people
- Sponsor
- University Hospital of North Norway
Severe Bipolar I Disorder (Diagnosis), Bipolar I Disorder, Most Recent Episode Mixed, in Remission
FIbrosis and Steatosis in Patients With Psychiatric Illness
Background: Severe psychiatric diseases (schizophrenia, bipolarity, depression, anxious syndrome) are often associated with a metabolic syndrome, including Non-Alcoholic Steato Hepatitis, probably misdiagnosed in patients with…
- Conditions
- Severe Bipolar I Disorder (Diagnosis), Bipolar I Disorder, Most Recent Episode Mixed, in Remission, Depression Psychotic Feature, Mood-Incongruent Delusion
- Trial name
- FibroPsy (NCT05965232)
- Testing
- Fibroscan
- Where
- France
- Volunteers
- 385 people
- Sponsor
- Centre Hospitalier Esquirol